Question for written answer E-002993/2021
to the Commission
Rule 138
Maria Arena (S&D), **Anja Hazekamp** (The Left), **Martin Hojsík** (Renew), **Frédérique Ries** (Renew), **Cindy Franssen** (PPE), **Sven Giegold** (Verts/ALE)

Subject: Updating the information requirements for endocrine-disrupting chemicals

In line with its commitments under the Chemicals Strategy for Sustainability, the Commission has started the process of updating the information requirements to be able to identify endocrine-disrupting chemicals under the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) Regulation. In addition to the expert advice provided through the CARACAL (Competent Authorities for REACH and CLP (classification, labelling and packaging of substances and mixtures)) Subgroup on Endocrine Disruptors, we understand that the Commission has recently commissioned a cost-benefit analysis, which is meant to provide the basis for a future impact assessment. Can the Commission answer the following questions:

1. How does it justify the commissioning of a cost-benefit analysis in the light of the Court of Justice judgment in case T-521/14, according to which economic considerations are irrelevant for the identification of endocrine disruptors?

2. Will any such analysis only assess how the information requirements can best be updated to meet scientific needs, and not if they should be updated?

3. How will it make sure that economic considerations do not unduly affect which information requirements are scientifically necessary to properly identify endocrine-disrupting chemicals? What is the timeline for the delivery of this analysis and when it will be made public?